




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁴ : C12P 21/00, C12N 15/00, 1/00 A61K 39/00, A23J X, C07K X	A1	(11) International Publication Number: WO 86/ 04093 (43) International Publication Date: 17 July 1986 (17.07.86)
(21) International Application Number: PCT/US85/02493 (22) International Filing Date: 18 December 1985 (18.12.85) (31) Priority Application Number: 687,908 (32) Priority Date: 31 December 1984 (31.12.84) (33) Priority Country: US (71) Applicant: DUKE UNIVERSITY [US/US]; Durham, NC 27710 (US). (72) Inventor: KEENE, Jack, D. ; 1617 Shawnee Street, Durham, NC 27701 (US). (74) Agents: NEELEY, Richard, L. et al.; Oblon, Fisher, Spivak, McClelland & Maier, Crystal Square Five, Suite 400, 1755 S. Jefferson Davis Highway, Arlington, VA 22202 (US).		(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i>

(54) Title: METHODS AND COMPOSITIONS USEFUL IN THE DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES

**(57) Abstract**

A method for producing a protein antigen which is reactive with an autoantibody associated with an autoimmune disease in a host, which comprises introducing genetic information from a cross-reactive donor gene library, into plural cells thereby producing transformed cells; selecting a producer cell which expresses said antigen by detecting a binding reaction between said autoantibody obtained from said host and a protein antigen expressed by a producer cell of said transformed cells which contains a gene coding for said protein antigen, thereby identifying a cloned DNA segment from said donor which can be utilized in the production of said protein, is disclosed along with biochemical reagents and products associated with this invention.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				

-1-

DescriptionMethods and Compositions useful in the
Diagnosis and Treatment of Autoimmune DiseasesTechnical Field

5 The present invention relates to methods and compositions useful in the treatment and diagnosis of autoimmune diseases and more particularly to such methods and compositions produced by genetic engineering.

10 Background Art

In normal humans and animals an individual will respond to exposure to a foreign substance by the production of specific antibodies or by developing cell-mediated immunity against the foreign substance.

15 Individuals are generally tolerant of substances which normally form a part of themselves and are thus described as being self-tolerant. The development of an immunologic response to self is called autoimmunity and is the result of some breakdown of self-tolerance.

20 Various theories have been proposed to explain the development of autoimmunity. For example, viruses are thought to play an important role in the pathogenesis of autoimmunity as has been demonstrated in several animal models. The expression of viral antigens on the
25 surface of the host cells is considered to elicit autoantibodies to cell membrane antigens as well as to the viral antigens. It has also been proposed that autoimmunity is a disorder caused by abnormal

immunologic regulation, particularly a change in T-cell activity. A decrease in suppressor T-cell activity or an increase in helper T-cell activity would result in excess production of low levels of autoantibodies.

5 This theory finds support in the finding of autoantibodies in some normal persons without evidence of autoimmune disease and in various animal models. Gene control also appears to exist in at least some autoimmune diseases as certain mice strains have been

10 demonstrated to exhibit an autoimmune disease similar to systemic lupus erythematosus (SLE). A high correlation of SLE is also found in identical twins. Additionally, an association of autoimmune disease with genes located in the HLA-D locus has been noted in

15 adult rheumatoid arthritis and in multiple sclerosis.

Systemic lupus erythematosus (SLE) is a serious autoimmune disease which affects the collagen of the connective tissues of the human body. Since SLE may affect one or more of a large number of different

20 tissues or organs of the body, such as blood vessels, heart, kidneys, skin, serous membranes, etc., clinical diagnosis of SLE is often difficult since the symptoms may resemble a number of other diseases such as rheumatoid arthritis, skin cancer, serum sickness,

25 rheumatic fever, multiple myeloma, and Sjogren's syndrome.

It is important to be able to distinguish SLE from other diseases due to the high probability of kidney, central nervous system, and vascular damage from the

30 disease. For example, lupus nephritis is very frequent in the disease and is one of the most serious features of SLE. Nephritis is a frequent cause of death in SLE patients, and it would be most advantageous to be able

to detect SLE early enough to prevent or mitigate serious kidney damage.

It has been demonstrated that sera from patients with connective tissue disorders contain antibodies to many nuclear constituents. For example, circulating antibodies that react with native DNA (deoxyribonucleic acid) have been found to be highly specific to patients suffering from systemic lupus erythematosus. The appearance and exacerbation of the nephritis attendant in SLE appears to be related to the formation and deposition of antibody/DNA and other immune complexes in the kidneys and particularly the renal glomeruli. Although the exact reasons for the production of these antibodies and the reasons for their particular specificity to SLE are as yet unknown, the detection and measurement of these autoantibodies has become increasingly important in the clinical diagnosis and evaluation of this disease.

Recently, a precise method for measuring various small amounts of anti-DNA antibody has been developed using ¹⁴C-labeled DNA. See T. Pincus et al, "Measurement of Serum DNA-Binding Activity In Systemic Lupus Erythematosus," New England Journal of Medicine, 281, 701-705 (1969). This method appears to be the most definitive test for SLE presently available. It is reported to be positive in 75 percent of SLE patients studied, whereas other leading tests were positive in only about 25-64 percent of SLE cases. Moreover, this anti-DNA antibody test has shown greater specificity for SLE than other diagnostic tests used, such as immunodiffusion, complement-fixation, and precipitation.

However, this test is a test for antibodies that react with DNA although DNA may not be the authentic antigen. Furthermore, this method is not applicable to autoimmune disorders in which the antigen is a protein. Protein antigens are associated with most forms of SLE as well as other types of autoimmune diseases. Such protein antigens are useful in diagnostic and treatment methods as a result of the ability to react specifically with autoantibodies associated with an autoimmune disease. However, isolation and purification of these antigens have heretofore been not been fruitful because of the scarcity and instability of antigenic material and because of the complexity of the separation techniques. Accordingly, a method for producing protein antigens which are reactive with an autoantibody associated with an autoimmune disease in a host is still needed.

Disclosure of the Invention

It is an object of this invention to provide a method for producing a protein antigen which is reactive with an autoantibody associated with an autoimmune disease.

It is a further object of this invention to provide a method capable of producing such antigens in large amounts and without requiring donation of large amounts of material from a host.

These and other objects of the invention as will hereinafter become more readily apparent have been accomplished by providing a method for production of a protein antigen which is reactive with an autoantibody

associated with autoimmune disease in a host, which comprises introducing genetic information from a cross-reactive donor gene library into plural recipient cells, thereby giving transformed cells; selecting a
5 cell which expresses said antigen by detecting a binding reaction between said autoantibody obtained from said host and a protein antigen expressed by a producer cell of said transformed cells which contains a gene coding for said protein antigen; cultivating
10 said cell which expresses said antigen in a culture medium; and isolating said protein antigen from said culture medium.

It is also an object of this invention to provide recombinant DNA molecules useful in the practice of the
15 method of the invention as well as methods of using the protein antigens, now available for the first time in large quantities, for the diagnosis and treatment of autoimmune diseases.

Brief Description of the Drawings

20 A more complete appreciation of the invention and many of the attendant advantages thereof will be readily obtained by reference to the following detailed description when considered in connection with the accompanying drawings, wherein:

25 FIGURE 1(a) is a series of photographs of culture media showing isolation and identification of La cDNA clones by immunological screening of λ gt11 recombinant phage plaques with lupus sera of the La specificity.

FIGURE 1(b) is a series of photographs showing
30 immunological screening of λ gt11-La clones with lupus

sera of various specificities.

FIGURE 2 is a series of photographs showing enzyme-linked immunosorbent assay (ELISA) using expressed La antigen bound to nitrocellulose and
5 reactive with sera from 18 patients with autoimmune diseases and two normal sera.

FIGURE 3 shows a restriction map of the 1.5 kb La protein cDNA.

FIGURE 4 is a photographic reproduction of a
10 series of acrylamide gel electrophoreses showing in vitro translation of hybrid-selected HeLa-cell mRNA using cDNA for La protein.

FIGURE 5 is a photographic reproduction of partial peptide mapping of the La protein showing in vivo
15 radioactively labeled HeLa-cell La protein.

Best Mode for Carrying Out the Invention

The present invention arose in part with the recognition that several cDNA clones obtained from a human liver expression library were recognized by
20 autoantibodies associated with certain autoimmune disorders. Prior to the present invention it was not known that peptides reactive with autoimmune antibodies could be produced in this manner. Additionally, if a physician or investigator wanted an antigen from a
25 particular patient or other affected individual, it was necessary to isolate the antigen from that source. Such antigens were generally not free in solution and were in any event available in only minute quantities, making this identification, analysis, and use

practically impossible, since the production of large quantities of antigen required large quantities of material from the affected human or animal, to the detriment of that individual.

5 Since the source which donated the original messenger DNA from which the cDNA clones were produced in the inventor's laboratory was not the same as the source of the autoantibodies, it was recognized that protein antigens which are reactive with autoantibodies
10 associated with an autoimmune disease, which were not previously available in large quantities, could be produced requiring no more than a serum sample from a host having an autoimmune disease by reacting the serum or antibodies derived therefrom with a cDNA library
15 from a different source. Accordingly, the present invention makes available for the first time an effective means for treating autoimmune diseases in a host in a manner specific for that host.

By "host" is meant any human or animal afflicted
20 with an autoimmune disease. Although the invention was first demonstrated with a human host and it is anticipated that human hosts will remain an area of interest, the present invention can also be used in the field of veterinary medicine. For example, horses,
25 cattle, sheep, and fowl (e.g., chickens, ducks, and turkeys), primates, dogs, cats, pigs, goats (especially for treatment of goat arthritis), and mink (especially for treatment of Aleutian mink disease).

One reagent used in the practice of the invention
30 is antiserum (or a purified antibody) from the host serum. A serum or plasma sample is obtained from a host, typically by veinipuncture, and red blood cells

and clots are removed. Antibodies are then separated from other proteins by any suitable technique. The antigenic reactivity of the host is determined by immunoprecipitation of radio labelled host-cell
5 extracts or by immunoblotting of unlabelled host-cell extracts. In both cases the reactive antigens are characterized by molecular weight fractionation (acrylamide gel electrophoresis) and bonding of immuno complexes to protein A from Staphylococcus aureus as
10 described in Towbin et al, Proc. Natl. Acad. Sci. USA, 76, 4350-4354 (1979) and Francoeur et al, Proc. Natl. Acad. Sci. USA, 79, 6772-6776 (1982), although many other methods for carrying out these reactions are equally suitable.

15 Another reagent needed for the practice of the present invention is a gene library from a donor species sufficiently related to the host so as to produce a cross-reactive protein antigen. As used in this specification, "gene library" refers to a
20 collection of vectors having operationally inserted therein or attached thereto DNA fragments from a cell or cells of the donor species. Since the host and donor, as described in this specification, are eucaryotic organisms, complementary DNA (cDNA)
25 libraries are particularly preferred although not necessary since antigenic determinants may be present on proteins produced from DNA segments which contain both introns and functional gene segments when these DNA segments are expressed as peptides in recipient
30 unicellular organisms. However, it is well recognized that cDNA produced from messenger DNA and thereby lacking the introns which are normally present in eucaryotic cells has a higher success rate in expressing proteins when inserted into procaryotic

recipient cells, and use of a cDNA library is accordingly preferred.

It will be recognized by those skilled in the art, armed with the disclosure set forth in this specification, that the donor species need not be the same as the host species. However, it is required that the donor species be capable of expressing a protein having an antigenic site (determinant) cross-reactive with the autoantibody of the host. Selection of a donor species can easily be accomplished by radioactively labeling cultured cells from a proposed donor species (with, for example, ³⁵S methionine), preparing a crude cell extract from the cultured cells, and immunoprecipitating the cell extract with autoantibody obtained from the host together with protein A from Staphylococcus aureus. If radioactivity is precipitated, an antigen is present in the donor cell extract that is reactive with the autoantibody obtained from the host, and the gene library from this donor can be used in the method of the invention. Alternatively, the donor species or a specific tissue from the donor can be extracted, and the extracted proteins can be fractionated in a matrix. The separated proteins are immobilized by transfer to a membrane and reacted with the autoantibody from the host. If protein A from Staphylococcus aureus binds to the filter, a corresponding gene library from the donor tissue can be used in the method of the invention. Nevertheless, in order to increase the percentage of producer cells (cells which produce a suitable protein antigen) in a given transformation, it is preferred that the donor and the host be in the same genus, preferably in the same species, although use of a mammalian donor with a mammalian host is also suitable.

-10-

By "cross-reactive" in this application is meant that an autoantibody of the host reacts with a protein antigen produced by the donor. This donor protein antigen need not be identical with the normal protein antigen present in the host that provides the antigenic determinant for the autoantibody associated with the autoimmune disease of the host. Cross-reactivity is defined by the ability of the antigen in question to react with the autoantibody. Naturally, if the protein antigens are identical, cross-reactivity will exist. However, it is also possible for the cross-reactive antigen to comprise in whole or in part a different biochemical composition from that of the host antigen.

Within the rheumatic diseases, and in particular with respect to systemic lupus erythmatosus, there are distinct classes of clinically defined autoantibodies that can be termed major and minor. The major class consists of four conventional protein antigenic specificities known as La, Ro, Sm, and RNP. Although most human hosts contain mixtures of these specificities, many hosts can be identified using the methods of immunoprecipitation and immunoblotting described above, as having a unique, single class of reactive La, Ro, Sm, or RNP autoantibody. Therefore, in the practice of this art, autoantibodies from selected hosts with a single antigenic specificity can be used to obtain genetic recombinants from donor libraries that will be commonly reactive with every host of the same conventional specificity or class. In SLE, greater than one half of all patients demonstrate autoantibodies reactive with one of these four major specificities or classes. Methods as described herein will allow those experienced in the art to produce purified antigens of each class as general diagnostic or

therapeutic reagents for other individuals containing autoantibodies of the same specificity or class.

The phrase "genetic information" generally refers to DNA which codes for all or part of the protein antigen. However, this phrase also encompasses RNA when used with an RNA virus or other vector based on RNA.

A cell which has received genetic information coding for the protein antigen and which expresses the protein antigen whether retained intracellularly or released into the culture medium, is referred to as a "producer cell."

The term "vector" is well understood and is synonymous with the often-used phrase "cloning vehicle". A vector is non-chromosomal double-stranded DNA comprising an intact replicon such that the vector is replicated when placed within a unicellular organism, for example by a process of transformation.

A material is "purified" when it does not contain other components that would interfere with the reactivity or property being sought and that would be present in the material as naturally formed. More preferably, purified material contains at least 95% by weight, even more preferably 99%, and most preferably 99.8%, of a single material. Water is not counted in measuring purity.

Advances in biochemistry in recent years have led to the construction of "recombinant" vectors in which, for example, plasmids are made to contain exogenous DNA. In particular instances the recombinant vector

can include heterologous DNA, by which is meant DNA that codes for a polypeptide ordinarily not produced by the organism susceptible to transformation by the recombinant vector. The production of recombinant DNA
5 vectors in the process of producing a gene library is well understood and need not be described in detail. However, a brief description of this process is included here for reference.

For example, a plasmid vector can be cleaved to
10 provide linear DNA having ligatable termini. These termini are bound to exogenous DNA having complementary like ligatable termini to provide a biologically functional recombinant DNA molecule having an intact replicon and a desired phenotypical property. A
15 variety of techniques are available for DNA recombination in which adjoining ends of separate DNA fragments are tailored to facilitate ligation. Ligation refers to the formation of phosphodiester bonds between adjacent nucleotides, most often through the agency of
20 the enzyme T_4 DNA ligase. Thus, blunt ends may be directly ligated. Alternatively, fragments containing single strands at their adjoining ends that will bond to complementary single strands by hydrogen bonding can be ligated. Such single strands, referred to as
25 cohesive termini, can be formed by the addition of nucleotides to blunt ends using terminal transferase. However, restriction endonucleases are most commonly used to produce cohesive termini. These enzymes cleave phosphodiester bonds in and around unique sequences of
30 nucleotides of about 4-6 base pairs in length. Many restriction endonucleases and their recognition sites are known, the so-called Eco RI endonuclease being the most widely known. Typically, a plasmid or other cloning vehicle is cleaved, leaving termini each

comprising half the restriction endonuclease recognition site, and a cleavage product of exogenous DNA obtained with the same restriction endonuclease having complementary ends is inserted into the cleaved
5 vector. Many variations of these techniques are known to those skilled in the art and can be used in the practice of the present invention.

The exogenous, i.e., donor, DNA used in producing the gene library of the present invention is obtained
10 from suitable cells of a donor identified as described above. When a cDNA donor gene library is being produced, it is preferred to use cells obtained from an organ of the mRNA donor that is the same as the organ attacked by the autoimmune disease in the host. For
15 example, if an autoimmune disease attacks the liver of a host, liver cells from the donor are preferred since cells of different organs are more likely to express peptides which are not reactive with the autoantibody against which protection is desired. When cDNA
20 fragments are being prepared, messenger DNA is obtained from the donor cells by any of the various techniques which exist for this purpose.

For example, the following method can be used to isolate messenger RNA from any mammalian tissue or cell
25 culture that can be dispersed into single cells. A more detailed description of this technique is given in Maniatis et al, molecular cloning: a laboratory manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1982, pages 191-199, which is herein
30 incorporated by reference. Cells are separated from the culture medium and washed in phosphate-buffered saline. The cells are then centrifuged to remove the supernatant and resuspended in a lysis buffer

containing approximately 1,000 units/ml RNasin or 10 mM vanadyl-ribonucleoside complexes. After mixing, storing, and centrifuging on a gradient, the cytoplasmic layer is recovered and added to a buffer containing a denaturing agent. A proteinase is then added to destroy protein. Proteins are removed by extracting once with phenol/chloroform. The aqueous phase is recovered and stored after ethanol has been added. The stored solution is then centrifuged to obtain a pellet containing nucleic acids. The nucleic acids are redissolved in a small volume of buffer containing RNasin or vanadyl-ribonucleoside complexes. A DNase is added to destroy DNA. After incubation, the resulting material is extracted once with phenol/chloroform. A solution of sodium acetate is added and the nucleic acids are precipitated with ethanol. Precipitated RNA is stored in aqueous ethanol at -70°C. As alternatives, the guanidinium/hot phenol method and the guanidinium/cesium chloride method may be used. Both of these techniques are described in the Maniatis et al publication cited above. If desired, polyadenylated RNA can be separated from nonpolyadenylated RNAs. The method of choice is chromatography on oligo (dT)-cellulose, which can be prepared in the laboratory or obtained commercially. A detail technique for selection of polyadenylated RNA is set forth in the Maniatis et al publication cited above.

Complementary DNA is then produced from the isolated mRNA by the enzyme reverse transcriptase. The resulting single-stranded DNA is converted into double-stranded DNA using DNA polymerase. When cDNA is produced in this manner from all the mRNA that is present in a cell and is inserted into a cloning vehicle, the resulting collection of cDNA is referred

to as a "donor gene library" since it contains DNA sequences coding for the gene products of the donor that were being expressed at the time the original mRNA was collected.

5 It should be noted that the production of a donor gene library by itself is well known and that this discussion of producing a donor library is merely to point out the nature of the biochemical reactions that are carried out in the practice of the present
10 invention. The invention does not depend on the existence of a particular gene library but can use any gene library, whether compiled specifically for the purpose of this invention or for any other purpose, that meets the requirements set forth in this
15 specification.

The vector used in the production of the host gene library can be any vector that replicates in a unicellular organism. For example, many plasmids suitable for use in the practice of this invention have
20 been described in recent U.S. patents such as U.S. Patents 4,273,875; 4,304,863; 4,419,450; 4,403,036; 4,363,877; 4,356,270; 4,349,629; and 4,332,901. Other vectors suitable for use in the practice of this invention include pAJ 655 (host bacteria, E. Coli FERM-
25 BP 136), pAJ 611 (host bacteria, E. Coli FERM-BP 138), pAJ 440 (host bacteria, Bacillus Subtilis ATCC 391391), pAJ 1844 (host bacteria, E. Coli FERM-BP 137), and pAJ 3148 (host bacteria, Corynebacterium glutamicum ATCC 39137). Particularly preferred is the phage vector
30 λ gt11 which can be produced from publically available phages according to the procedure described in Young et al, Proc. Natl. Acad. Sci. USA 80 1194-1198 (1983). Briefly, this preferred phage vector can be

-16-

produced as follows:

5 λ gt7-lac5 and λ 540 (Δ B imm21 nin5) are cleaved with HindIII, and the fragments are pooled and then ligated with T4 DNA ligase. The desired phage recombinant produces turbid (imm21) blue (lac5) plaques when the DNA is transfected into E. coli BNN93 and cells are plated on medium containing the chromogenic indicator 5-bromo-4-chloro-3-indolyl β -D-galactoside (X-Gal). The λ gt7-lac5- λ 540 hybrid is then crossed with
10 λ gt4 (cl857 S100 nin5) and recombinants, grown at 42°C, are scored for the formation of clear (cl857) blue plaques on X-Gal plates. The presence of the amber mutation S100 is confirmed by examining relative plating efficiency on hosts that contain or lack the
15 amber suppressor supF (BNN45 or BNN93, respectively). Finally, the lac5 cl857 S100 phage is mapped for EcoRI cleavage sites. The phage λ gt11 contains a single EcoRI cleavage site.

Once a donor gene library is available, either
20 according to the procedures described above or by any other procedure, recipient cells are transformed with the gene library to produce a series of transformed cells containing the various donor DNA (or cDNA) fragments. The incorporation of the recombinant DNA
25 into recipient cells can be accomplished by treating the recipient unicellular microorganisms with calcium chloride to increase the permeability of the cell membranes to DNA, as is reported in Mandel et al, J. Mol. Biol., 53 159 (1970). Other methods for
30 transforming recipient cells include incorporating the recombinant DNA at a stage of growth when cells become capable of incorporating DNA (the so-called competent cell stage) as is reported in Young et al, Gene, 1, 153 (1977). Plasmids can also be incorporated into DNA

recipients by forming protoplasts or spheroplasts of the DNA recipients (particularly used for yeast), as described in Chang et al, Mol. Ec. Gen. Genet., 168, 111 (1979). Any other method of transforming recipient
5 cells can be used in the practice of this aspect of the invention.

Autoimmune antigens can be obtained from recipient cells using any of a multitude of known techniques. For example, cells that express peptide antigens in a
10 manner such that the antigens are transported through the cell membrane into the surrounding space can be grown in a culture medium, and the desired antigen can be obtained directly from the medium. If the desired antigen is retained inside the cell membrane, cells can
15 be lysed to release the antigen into the cell supernatant, which can then be purified to obtain the desired antigen. If the antigen being produced has an adverse effect on the cell expressing the antigen, placing the gene for the antigen under the control of
20 an inducer allows expression of the gene only at the time of collection. For example, a λ phage can be grown on cells containing pNC9, a PBR322 derivative containing laci^Q. Sufficient lac repressor is produced in the cells to repress expression of the hybrid
25 protein during phage lytic growth. Expression of the hybrid can be induced in infected cells with IPTG, and the antigen so produced is released from the cells upon cell lysis.

When the λ gt11 phage is used in one of the
30 preferred aspects of the invention, the following procedure is preferred for screening with antibodies to determine the presence of autoimmune antigens. A recommended host is E. coli Y1090, which is

AlacU169 proA⁺ Δlon araD139 strA supF [trpC22::Tn10] (pMC9). The host bacterium is infected and plated in soft agar, after which the plate is incubated for approximately 5 hours at about 42°C. For even distribution of phages, approximately 10⁴ phages per small plate and 10⁵ phages per large plate is recommended. The plate is overlaid with a dry nitrocellulose filtered disk, previously soaked in 10 mM IPTG. The plate is incubated at approximately 37°C. The filter is then removed and washed in tris-buffered saline, pH 8.1 at room temperature for approximately 5-10 minutes. The filter is then incubated in TBS containing about 20% fetal cast serum (or 3% BSA or Ovalbumin). Incubation is for approximately 30 minutes at room temperature. The filter is then incubated in TBS +20% fetal cast serum plus antibody (approximately a 1:1 dilution of serum or IgG; if IgG is used, IgG is initially present at 10 mg/ml). Incubation occurs for approximately one hour at room temperature. The filter is then washed to remove unbound antibody and incubated in TBS containing 125 I-protein A (approximately 10⁶ cpn/filter) for about one hour at room temperature. Radioactivity will be present at locations where antibody binding indicated the presence of expressed antigen.

Although this technique represents a preferred embodiment of the invention, other methods of screening with antibody probes are known to those skilled in the art and can readily be used in place of this technique.

The word "transformant" is used in this application in its broadest sense to refer to any recipient cell which has exogenous genetic information inserted therein. In addition to the more restricted meaning of

transformant (a cell which has incorporated an plasmid), transformant in this application refers to cells which have exogenous DNA inserted into their chromosome (or chromosomes) as well as to cells which
5 contain any recombinant vector as described above.

The plural recipient cells which are transformed using a donor gene library are referred to as expression libraries since the transformants will express gene products from the recombinant DNA vectors
10 that have been randomly inserted into the individual unicellular organisms. Typically, the transformants are cloned to produce a series of cell lines arising from individual original transformants. A sample is selected from each cell line and (after lysing if
15 desired) is exposed to the autoantibody associated with the immune disease in the host prepared as described above. Binding interactions between the autoantibody and the antigen expressed by the transformant containing the proper gene can be detected by any of
20 the various methods available for this process. For example, proteins from colonies of transformants can be adsorbed onto nitrocellulose filter paper overlayed on the colonies followed by addition of the autoimmune antibody, washing to remove unreacted antibody, and
25 detecting protein-found antibody with radioactively labeled protein A. Cell colonies identified in this manner can be grown in large quantity to provide the desired amount of the gene coding for the protein antigen. At this point, several variations are
30 possible. The cells containing the gene for the protein antigen can be allowed to express the antigen and the antigen can be recovered from the culture medium using known techniques. Alternatively, the donor cDNA fragment can be excised from the first vector

(e.g., by excision with the same endonuclease used to cleave the plasmid and insert the DNA originally), inserted into a new cloning vector, and used to transform a recipient cell for a large scale production of the cDNA or the protein antigen. Alternatively, it is also possible, once relatively large quantities of the protein antigen or the cDNA which produces it are available, to determine the sequence of the molecular species. Once this sequence is known, it is possible to synthesize the peptide antigen using an automated peptide synthesizer or other suitable means of synthesis. Both laboratory techniques of synthesis, typically solid-phase synthesis, and automated peptide synthesizers are well known in the art. See, for example, page 34 of the November/December 1984 issue of Genetic Engineering News, which contains a commercial advertisement for such equipment. Since a given DNA sequence will code for a single peptide, the genetic information present in the cloned DNA segment can readily be used in a non-biological synthesis of a peptide. Since hydrophobic regions of a peptide are generally on the interior of the peptide and hydrophilic regions are generally on the exterior, it is possible to predict with reasonable certainty those portions of the peptide that will be on the exterior surfaces and therefore available to act as antigenic determinants. Hydrophilicity analysis using the method of Hopp and Woods, Proc. Natl. Acad. Sci. USA, 78, 3824-3828 (1981), can be used to identify regions of peptides having high hydrophilicity. Antigenic determinants often have a sequence of 3-10 amino acids with higher than average hydrophilicity values. Artificial peptides produced using the genetic information preferably contain the entire hydrophilic region as described above. More preferably, artificial

peptides have a sequence sufficiently identical to the sequence coded by the cloned DNA segment to make the antigenic determinant available for reaction with the autoantibody. An identical sequence is most preferred, but it will be readily recognized by those skill in the art that minor modifications in the protein structure can be made without affecting the antigenic determinant. For example, substitution of closely related amino acids (leucine for isoleucine) and production of peptides with substituted (e.g., cysteine) or missing terminal amino acids (preferably no more than 10 percent of the total amino acid content) are both possible.

Other typical modifications include addition of different amino acids to allow coupling of the antigen to various surfaces. For example, addition or substitution of a cysteine allows attachment of the sulfhydryl group to a functionalized surface and addition or substitution of hydrophobic amino acids allows attachment by hydrophobic bonding to plastic surfaces. Both of these methods can be used, for example, in ELISA assays and other standard immunoassays. Modifications which fall within the scope of the present invention can readily be determined by their ability to react with the autoimmune antibody.

Any of these or other equivalent methods are suitable for obtaining an antigen which is reactive with the autoantibody associated with the autoimmune disease of the host from which serum was originally obtained.

In addition to the above general procedures which can be used for preparing recombinant DNA molecules and

transformed unicellular organisms in accordance with the practices of this invention, other known techniques and modifications thereof can be used in carrying out the practice of the invention. In particular, techniques relating to genetic engineering have recently undergone explosive growth and development. Many recent U.S. patents disclose plasmids, genetically engineered microorganisms, and methods of conducting genetic engineering which can be used in the practice of the present invention. For example, U.S. Patent 4,273,875 discloses a plasmid and a process of isolating the same. U.S. Patent 4,304,863 discloses a process for producing bacteria by genetic engineering in which a hybrid plasmid is constructed and used to transform a bacterial host. U.S. Patent 4,419,450 discloses a plasmid useful as a cloning vehicle in recombinant DNA work. U.S. Patent 4,362,867 discloses recombinant cDNA construction methods and hybrid nucleotides produced thereby which are useful in cloning processes. U.S. Patent 4,403,036 discloses genetic reagents for generating plasmids containing multiple copies of DNA segments. U.S. Patent 4,363,877 discloses recombinant DNA transfer vectors. U.S. Patent 4,356,270 discloses a recombinant DNA cloning vehicle and is a particularly useful disclosure for those with limited experience in the area of genetic engineering since it defines many of the terms used in genetic engineering and the basic processes used therein. U.S. Patent 4,336,336 discloses a fused gene and a method of making the same. U.S. Patent 4,349,629 discloses plasmid vectors and the production and use thereof. U.S. Patent 4,332,901 discloses a cloning vector useful in recombinant DNA.

All of these patents as well as all other patents

and other publications cited in this disclosure are indicative of the level of skill of those skilled in the art to which this invention pertains and are all herein incorporated by reference.

5 Although some of these patents are directed to the production of a particular gene product that is not within the scope of the present invention, the procedures described therein can easily be modified to the practice of the invention described in this
10 specification by those skilled in the art of genetic engineering. For example, the production of fused proteins can provide increased protein and antigenic stability, which is useful in the practice of the described invention. Antigens reactive with
15 autoantibodies are normal host constituents and are especially susceptible to degradation. For long-term storage in diagnostic and large-volume exposure in therapeutic aspects of this invention, enhanced stability is desired. In addition, for a variety of
20 different antigenic materials to be applied in a common diagnostic or therapeutic device, a common fused protein moiety (e.g., β -galactosidase) can enhance the flexibility of the method.

 Although the method of the invention can be used
25 in the treatment of any autoimmune disease, it is particularly preferred for use in SLE and associated autoimmune disorders such as scleroderma, sicca syndrome, mixed connective tissue disease (MCTD), and Sjogren's syndrome.

30 Antigens identified and produced by the method of the present invention have many uses, for example in the identification and treatment of autoimmune

disorders. In many autoimmune disorders, symptoms are alleviated by removal of autoantibodies from the afflicted human or animal. Selective removal is desired so that the afflicted host can still be able to exhibit normal immune responses to exogenous antigens. As discussed in Terman et al, Clinical Immunology and Immunopathology, 8, 90-96 (1977), removal of DNA antibodies in vivo has been accomplished by extracorporeal circulation of blood over DNA immobilized on charcoal. This technique can easily be adapted for use with autoimmune diseases involving protein antigens by replacing the DNA immobilized on charcoal by appropriate protein antigens produced as described herein immobilized on a suitable substrate. Another example of a method and an apparatus for treatment of autoimmune diseases is set forth in U.S. Patent 4,362,155. This patent discloses removing interferon and/or autoantibodies from blood. The method and apparatus can be readily adapted to use the antigens disclosed in the present invention instead of the general adsorbants disclosed in the patent.

The purified antigens that are reactive with patient autoantibodies can be attached to solid matrices and used to deplete, trap, or otherwise remove the reactive autoantibodies from the plasma of afflicted hosts. Methods for attaching peptides to surfaces are well known and can readily be adapted for use with this invention. For example, a terminal amino acid of a peptide antigen can react with a reactive carbonyl, carboxylate, hydroxyl, or amino group of a solid polymer (or of a linking group attached to the polymer). Coating of unmodified peptide on plastic or glass surfaces can also be used to provide an immunologically reactive surface.

Patients with autoimmune diseases such as myesthemia gravis and systemic lupis as well as those with some forms of cancer have been successfully treated with subtractive therapies in which all antibodies are depleted from the blood of the patient. These methods have suffered from the non-availability of chemically pure, reactive antigens, the method described herein provides for the first time large amounts of antigenic proteins that can be used to deplete the host plasma of specific autoantibodies. Thus, in practice, the beneficial antibodies can be returned to the host, thus avoiding the use of expensive and potentially complicating replacement fluids (e.g., albumin).

For example, patients with SLE or Sjorgen's syndrome that produce autoantibodies that react with the La protein can encounter a crisis of cellular destruction and inflammation. Such a patient can be treated by circulation or percolation of her serum through an apheresis device in which genetically produced La protein has been incorporated at high concentrations. The device can be designed such that every potential La autoantibody is disposed to an immobilized La antigen. The antigen can be attached to the solid matrix by means of a protein portion that has been genetically fused and expressed (e.g., β -galactosidase or a strong matrix binding protein such as avidin). Attachment by means of a fused handle, arm, or tag will have the advantages of (1) allowing a common chemical attachment source so that various antigens can be identically conjugated to a common matrix, (2) allowing maximum freedom of mobility of the antigen, a quality that is known to improve antibody-antigen reactivity, and (3) providing for enhanced

stability of the antigen. The resultant subtraction of La autoantibodies from the patient's blood will prevent or alter the ability of immuno complexes to form, and deposition of complexes in inflamed tissues of a patient can be reduced. The initial step in this procedure requires the subtraction of preformed La immune complexes using crude plasmapheresis or immunoglobulin depletion with staph protein A followed by specific depletion of the newly produced La autoantibodies before they can encounter antigens in the host with which to react. Thus, the blood of the patient could then remain free of immune complexes containing the La antigen.

Protein antigens produced according to the invention could also be used by direct injection of the antigen into the afflicted host in order to perturb the formation of immune complexes. Immune complexes that form as a result of autoimmunity depend upon the presence of critical concentrations of the reactants (antigen and antibody), and the ratio of the reactants one to another determines whether binding will occur. This ratio is presumed to be optimal during periods of crisis in the autoimmune disease state. By the method of the present invention, homogeneously pure antigens can be injected into the blood of the host and thus alter the antigen-antibody ratio. The resultant failure to form new immune complexes will allow the reticuloendothelial system and phagocytes to successfully remove preformed immune complexes, thus diminishing the ability of the immune complexes to deposit in target tissues where they are associated with autoimmune pathology.

For example, purified La antigen can be injected

intervenously into a patient who is producing La autoantibodies during a life threatening autoimmune crisis in which immune complexes with La antigen are forming more rapidly than they can be cleared and destroyed. In an average human host of 68 kg weight with 4.8 liters of whole blood, there are about 5×10^4 mm of IgG. In typical patients with circulating La autoantibodies, this represents an approximate equivalence of 10^{15} molecules of La antibody in total. Thus, injection of a molar equivalence of La antigen (approximately 1.6 nanomoles) would prevent formation of immune complexes that optimally result during states of high antibody-low antigen ratios. The current hypothesis of autoimmunity based upon formation of pathogenic immune complexes at the site of deposit rather than in free circulation maintains that the presence of a high-affinity antigen in circulation should decrease the rate of deposit of immune complexes in target tissues. In order to properly determine the quantity of circulating autoantibodies, the quantitative diagnostic methods described in the present invention can be applied, and the quantity of purified antigen injected can be adjusted accordingly as the level of autoantibodies rises or falls.

The invention now being generally described, the same will be better understood by reference to certain specific examples which are included herein for purposes of illustration only and are not intended to be limiting of the invention or any embodiment thereof, unless specified.

Example

Isolation and Analysis of cDNA clones expressing the human lupus La antigen.

Introduction

5 The present invention has been reduced to practice and illustrated by the identification of recombinant cDNA clones made from human liver that express the La protein associated with systemic lupus erythematosus and Sjorgen's syndrome. Prior to the present invention
10 there was no method known that would allow identification of the specific antigenic material, and only approximate assignment of antigenic specificities against standard prototype antisera was possible (1). The mammalian cell La protein was found associated with
15 precursor forms of RNA polymerase III transcripts including tRNA, 4.5S RNA, 5S RNA, and 7-2 RNA (3,4,5,6). Some small viral transcripts such as VAI RNA of adenovirus (7,8), EBER RNAs of Epstein-Barr virus (9) and the leader RNAs of vesicular stomatitis
20 virus (2,10) and rabies virus (11) were also shown to be complexed with the La protein. By immunoprecipitation of ribonucleoprotein complexes using La antibodies, the site of La protein binding to several of these RNA species was shown to reside near the 3'
25 end (4,8,12). The presence of uridylate residues at the 3' ends of these RNAs may be required for binding. Furthermore, the addition of extra 3' terminal uridylate residues was found to enhance the binding of La protein to VAI RNA (13) and to transfer
30 RNA (14). Because La protein preferentially binds to unprocessed transcripts, Steitz and coworkers (4,5) have proposed that La protein is a transcription factor

for RNA polymerase III. Despite uncertainty regarding its exact function in RNA metabolism, it is clear that the La protein is biologically important in the regulation of gene expression because it associates
5 with a variety of cellular and viral RNAs, many of which have known functions.

To further characterize the biochemical functions of the La protein, attempts have been made to purify it from mammalian cells (14). Recoveries from these
10 purification procedures have been less than 7% and the La protein showed biochemical heterogeneity apparently due to interactions with RNA components. In order to produce large amounts of highly purified La protein, the inventors derived recombinant cDNA clones that code
15 for La protein. La-cDNA colonies from λ gt11 expression libraries (15) were identified using sera from selected lupus patients as antibody probes.

MATERIALS AND METHODS

Enzymes

20 Enzymes were purchased from Bethesda Research Laboratories and New England Biolabs. Rabbit reticulocyte lysate system for in vitro translation was from New England Nuclear.

Antisera

30 Lupus antisera were obtained from the Duke University Medical Center Fluorescent Antinuclear Antibody Laboratory. Sera that were strongly reactive with single specific antigens were identified and obtained in larger quantities by venipuncture.

Cells and Immunoprecipitation

HeLa cells were labeled in methionine-free medium for 5 h with [^{35}S]-methionine (New England Nuclear) at 0.2-0.5 mCi/ml for antibody precipitations. Protein
5 extracts were prepared and immunoprecipitations were carried out as described (8) using Pansorbin (Calbiochem) as a source of protein A. Immunoprecipitated proteins were analyzed by 15% SDS polyacrylamide gel electrophoresis (PAGE) (16) followed by
10 fluorography.

Bacterial Strains and λ gt11 expression libraries

E. coli strains Y1088 and Y1090 were obtained from D. Stafford (University of North Carolina at Chapel Hill). Human liver cDNA libraries constructed with
15 λ gt11 were provided by D. Stafford and P. Modrich (Duke University Medical Center) and R.A. Lazzarini (National Institutes of Health).

Screening of expression libraries with antibody probes

As described by Young and Davis (15), λ gt11
20 recombinant phages were plated on E. coli Y1090 at 10^5 pfu per 576 cm^2 plate (NUCU Inter Med). Expression of β -galactosidase fusion proteins was induced by overlaying with nitrocellulose fibers (Schleicher and Schuell) that were saturated with 10 mM isopropyl
25 thiogalactopyranoside (IPTG) (Boehringer Mannheim Biochemicals). Sera from lupus patients were screened by immunoprecipitation of [^{35}S]-methionine- and [^3H]-amino-acid-labeled HeLa cell extracts to confirm the unique specificity of the autoantibodies or by

immunoblotting using the technique of Towbin et al,
Proc. Natl. Acad. Sci. USA, 76, 4350-4354 (1979). The
La sera were determined to be free of Ro, Sm, RNP and
other lupus autoantibodies prior to use in screening
5 expression libraries. After transfer of induced
proteins to nitrocellulose, the filters were blocked
with fetal calf serum, screened with 1:100 dilutions of
lupus antisera and probed with [¹²⁵I]-labeled protein A
(ICN Radiochemicals).

10 Hybrid selection in the in vitro translation

The Eco RI-DNA inserts, recloned into pBR322, were
immobilized on nitrocellulose filters and used for
hybrid selection. Total HeLa cell cytoplasmic RNA was
used in the hybrid selections as described by Maniatis
15 et al (17). Hybrid selected mRNAs were translated in
vitro using rabbit reticulocyte lysates in the presence
of [³⁵S]-methionine and the products analyzed by 15%
SDS/PAGE. Gel slices identified by autoradiography and
containing the La protein were transferred to sample
20 wells of a second gel. Varying amounts of S. aureus V8
protease (Sigma) were added to each well, and digestion
was allowed to proceed in the stacking gel according to
the method of Cleveland et al (18). The peptides
generated by limited proteolysis were fractionated in
25 the same gel and identified by fluorography.

DNA sequencing

Eco RI-inserts isolated from λ gt11-La clones were
fragmented using restriction enzymes and subcloned into
M13-mp18 and M13-mp19 vectors. Dideoxy DNA sequencing
30 (19) was carried out using [³⁵S]-dATP (Amersham) and
buffer gradient gels (20).

Enzyme-linked immunosorbent assay (ELISA)

Sheets of nitrocellulose soaked in 10 mM IPTG were coated with La antigen by induction of confluent phage plaques containing the clonally purified, full-length La cDNA. For more sensitive assays the partially purified β -galactosidase-La fusion protein was used to coat nitrocellulose sheets. Antigen-coated nitrocellulose sheets were treated with a BSA- containing blocking solution (Kirkegaard and Perry Laboratories), and dilutions of human sera were placed in contact with the antigen for 1 hr. The sera were removed and the filters thoroughly washed with buffer containing 0.02 M imidazole buffered saline and 0.02% Tween 20 (Kirkegaard and Perry Laboratories). The nitrocellulose sheets were washed for 10 min each in the Tween 20 buffer and twice in phosphate buffered saline (PBS). The antibody-reacted sheets were incubated with lactoperoxidase-conjugated protein A at a concentration of 1 μ g/ml for 30 min. After 3 cycles of washing, filters were reacted with 4-chloro-1-naphthol in the peroxidase substrate system (Kirkegaard and Perry) for 10 min.

RESULTS

Isolation and Identification of La-CDNA clones

Initial plaque screening of 500,000 recombinants identified twenty putative La clones. Upon several rounds of purification and rescreening with various La-specific autoantibodies, three positive La clones were isolated and confirmed. FIGURE 1(a) shows a series of photographs of culture media demonstrating isolation and identification of La cDNA clones by the immuno-

logical screening procedure. Recombinant phages were plated initially at a density of approximately 200 pfu/cm² on 576 cm² plates. A 0.5-cm-diameter agar plug at the position of each of the signals were removed and
5 titered before replating at a density of approximately 20 pfu/cm² on 9-cm-diameter plates and rescreened. The replating and rescreening process was repeated several times until each phage plug contained clonally purified recombinants, as determined when every plaque on the
10 plate was reactive with La antisera from several different patients.

When two of the La clones were expressed as gtl1 plaques and analyzed for reactivity with a panel of sera from patients with SLE that did not contain La
15 specific autoantibodies (as assayed by immunoprecipitation of RNA and protein, cell fluorescence (ANA) and counterimmunoelectrophoresis (CIE)) as well as with normal human sera, the data of FIGURE 1b were obtained. The sera used exhibited La, Sm and RNP
20 specificities. It is clear that clones that expressed La antigen were only reactive with sera from SLE patients of the La specificity.

These clonally expressed La antigens were further identified by an enzyme-linked immunosorbent assay
25 (ELISA). Results of a typical dot ELISA with one of the La antigen clones are shown in FIGURE 2. Sera from 18 SLE patients were analyzed for reactivity with the expressed La antigen. Sera from three SLE-La patients showed a clear positive response while patients with
30 other lupus specificities (Sm, Ro, RNP, Ga, To and unclassified reactivities) and normals showed only a low background of reactivity. Filters were prepared and processed as described in Materials and Methods and

analyzed by lactoperoxidase linked S. aureus protein
A. (1-2) La, (3) La/Ro, (4) Ro, (5) Sm, (6) RNP, (7)
SM/RNP, (8) Sm/RNP, (9) unknown SLE, (10) To, (11) RNP,
(12) RNP + unknown, (13) Sm/RNP, (14) RNP, (15) unknown
5 SLE, (16) Sm/RNP, (17) unknown SLE (La), (18) unknown
SLE (19) normal, (20) normal. In some cases, sera of
unknown specificity by ANA and CIE were found by the
ELISA to be weakly positive for La protein. Subsequent
analysis by RNA and protein precipitations confirmed
10 the presence of La antibodies in these samples (data
not shown).

Data from DNA-DNA hybridization (not shown) and
restriction enzyme analysis indicated that overlapping
La clones had been isolated, all of which contained the
15 carboxyl-terminal portion of the coding sequence. The
expected length of the coding sequence for the 50,000
dalton human La protein is about 1.5 kb. The largest
of the cDNA clones contained an insert of about 1.5 kb
and appeared to represent the near full-length coding
20 sequence. A partial restriction map is shown in
FIGURE 3.

Protein identity by hybrid selection and in vitro translation

To confirm the identity of the cDNA clones, the
25 techniques of hybrid selection and in vitro translation
were used. DNA inserts from the λ gt11-La clones,
subcloned into pBR322, were used for hybrid selection
of mRNA from total HeLa cytoplasmic RNA. The selected
filter-bound mRNA was eluted and translated in vitro
30 using rabbit reticulocyte lysates. FIGURE 4 shows a
fluorograph of the [35 S]-methionine-labeled products
synthesized in vitro, and fractionated on 15%

SDS/acrylamide gels.

The various gels are shown in FIGURE 4 as follows:

- 5 (a) Lane 1, in vivo [^{35}S]-labeled HeLa cell proteins immunoprecipitated with lupus sera of the La and Ro specificities. Lane 2, in vitro translated products from HeLa mRNA hybrid-selected with La cDNA insert. Lane 3, in vitro translated products from HeLa mRNA hybrid-selected with La cDNA plasmid. Lanes 4 and 5, 10 in vitro translated products from HeLa mRNA hybrid-selected with the plasmid pBR322. Lane 6, in vitro translated products using 10 μg of carrier tRNA.
- 15 (b) Lane 1, in vivo [^{35}S]-labeled HeLa cell proteins immunoprecipitated with lupus sera of the La specificity. Lane 2, same as lane 3 in (a). Lane 3, translated material from lane 2 immunoprecipitated with anti-La serum. Lane 4, same as 20 lane 4 in (a). Lane 5, same as lane 6 in (a). Lane 6, in vitro translated products using 0.1 μg of total HeLa cell RNA.

25 A single protein of approximately 50,000 daltons was the only protein species unique to the La-cDNA-selected mRNA (FIGURE 4a, lanes 2 and 3; FIGURE 4b, lane 2). This protein co-migrated with the in vivo labeled La protein immunoprecipitated by anti-La serum (FIGURE 4a and b, lane 1). The in vitro synthesized 30 species was found to be reactive with the same antiserum (FIGURE 4b, lane 3). To further demonstrate

that the in vitro translated protein was indeed the authentic cellular La protein, hybrid selection and translation and fractionated the products on preparative gels was carried out. Preparative gels were
5 autoradiographed, and the gel slices containing both in vitro and in vivo labeled La protein were transferred to sample wells of a second gel. Using the method of Cleveland et al (17), the samples were subjected to limited proteolysis with S. aureus V8
10 protease, and the peptides generated were analyzed. Fig. 5 shows a fluorograph of peptide mapping of the La protein synthesized in vitro and in vivo. In vivo [³⁵S]-labeled HeLa cell La protein and the co-migrating protein band synthesized in vitro with rabbit
15 reticulocyte lysates using La cDNA hybrid-selected mRNA were gel purified, digested with varying amounts of S. aureus V8 protease, and analyzed on a 15% SDS/acrylamide gel. Samples were incubated for 30 min. in the stacking gel with lanes 1-4 representing 0, 10,
20 100 and 1000 ng of protease, respectively. These data demonstrate that the in vitro translated product has the same partial proteolytic profile as the in vivo labeled La protein. Therefore, the cDNA clones code for and express the human La protein.

25 Mapping of an antigenic site of the La protein

Because λ gt11 expresses cDNA inserts in the correct reading frame, as defined by antigenicity, it was possible to determine the amino acid sequence from the DNA sequence starting immediately after the 5' Eco
30 RI cleavage site. The smallest cDNA insert isolated was 390 nucleotides long that included 366 bases coding for the carboxyl terminal 122 amino acids of La protein in addition to 24 nucleotides of noncoding informa-

tion. The coding sequence of another cDNA insert was found to include only the carboxyl terminal 55 amino acids. Because both cDNA inserts were expressed as -galactosidase fusion proteins in the gtl1 vector, at least one antigenic site reactive with La antisera resides in this 55-amino-acid region (terminal 12%) of the protein. The nucleotide and amino acid sequences are as follows:

```

10      GGC TGG GTA CCT TTG GAG ATA ATG ATA AAA   30
      gly trp val pro leu glu ile met ile lys

      TTC AAC AGG TTG AAC CGT CTA ACA ACA GAC   60
      phe asn arg leu asn arg leu thr thr asp

      TTT AAT GTA ATT GTG GAA GCA TTG AGC AAA   90
      phe asn val ile val glu ala leu ser lys

15      TCC AAG GCA GAA CTC ATG GAA ATC AGT GAA  120
      ser lys ala glu leu met glu ile ser glu

      GAT AAA ACT AAA ATC AGA AGG TCT CCA AGC   150
      asp lys thr lys ile arg arg ser pro ser

      AAA CCC CTA CTG AAG TGA 168
20      lys pro leu leu lys TERM
```

One in-frame termination codon was present beginning at position 166.

This sequence has a high content of hydrophobic amino acids. Hydrophilicity analysis using the method of Hopp and Woods (21) identified a decapeptide from amino acids 40 to 49 with a value of +1.61. The average hydrophilicity of the 55 amino acid antigenic portion was calculated to be +0.3. Based on this

method, this decapeptide region has a high probability of being exposed on the surface of the protein and may overlap with an antigenic determinant for La protein. Accordingly, this hexapeptide sequence, glu-asp-lys-
5 thr-lys-ile-arg-arg-ser-pro represents for the first time a unique antigenic determinant associated with an autoimmune disease.

The method as described above has also been applied to the production of clones expressing antigens
10 cross-reactive with natural Ro, L-42, Scl, and U₂bp antigens.

A deposit has been made with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.A. to exemplify this preferred
15 aspect of the invention. The deposit is identified as E. coli HB1010-Lab and by its deposit number, ATCC 39984. This strain comprises a pBR322 plasmid having a La antigen gene inserted therein and transformed into E. coli HB101.

References

1. Tan, E. M. (1982), "Autoantibodies to Nuclear Antigens (ANA): Their Immunobiology and Medicine," in Advances in Immunology, Vol. 33, 5 H. Kunkel and F. Dixon, eds., Academic Press, Inc., pp. 167-240.
2. Kurilla, M. G. and Keene, J. D. (1983), Cell 34, pp. 837-845.
3. Chambers, J. C., Kurilla, M. G. and Keene, J. D. 10 1983), J. Biol. Chem. 258, pp. 11438-11441.
4. Hendrick, J. P., Wolin, S. L., Rinke, J., Lerner, M. R., and Steitz, J. A. (1981), Mol. Cell. Biol. 1, pp. 1138-1149.
5. Rinke, J., and Steitz, J. A. (1982), Cell 29, 15 pp. 149-159.
6. Hashimoto, C. and Steitz, J. A. (1983), J. Biol. Chem. 258, pp. 1379-1384.
7. Lerner, M. R., Boyle, J. A., Hardin, J. A. and Steitz, J. A. (1981), Science 211, pp. 400-402.
8. Francoeur, A. M. and Mathews, M. B. (1982), Proc. 20 Natl. Acad. Sci. USA 79, pp. 6772-6776.
9. Rosa, M. D., Gottlieb, E., Lerner, M. R., and Steitz, J. A. (1981), Mol. Cell. Biol. 1, pp. 785-796.

10. Wilusz, J., Kurilla, M. G., and Keene, J. D.
(1983), Proc. Natl. Acad. Sci. USA 80, pp. 5827-5831.
- 5 11. Kurilla, M. G., Cabradilla, C. D., Holloway, B. P., and Keene, J. D. (1984), J. Virol. 50, 773-778.
12. Reddy, R., Henning, D., Tan, E., and Busch, H.
(1983), J. Biol. Chem. 258, pp. 8352-8356.
- 10 13. Mathews, M. B. and Francoeur, A. M. (1984), Mol. Cell. Biol. 4, pp. 1134-1140.
14. Stefano, J. E. (1984), Cell 36, pp. 145-154.
15. Young, R. A. and Davis, R. W. (1983), Science 222, pp. 778-782.
- 15 16. Laemmli, U. K. (1970), Nature (London) 227, pp. 680-685.
17. Maniatis, T., Fritsch, E. F., and Sambrook, J.
(1982), Molecular Cloning: A Laboratory Manual
(Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).
- 20 18. Cleveland, D. W., Fischer, S. G., Kirschner, M. W., and Laemmli, U. K. (1977), J. Biol. Chem. 252, pp. 1102-1106.
- 25 19. Sanger, F., Coulson, A. R., Barrell, B. G., Smith, A. J. H., and Roe, B. A. (1980), J. Mol. Biol. 143, 161-178.

20. Biggin, M. D., Gibson, T. J. and Hong, G. F.
(1983), Proc. Natl. Acad. Sci. 80, pp. 3963-3965.
21. Hopp, T. P. and Woods, K. R. (1981), Proc. Natl.
Acad. Sci. USA 78, pp. 3824-3828.

The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the
5 invention as set forth herein.

Claims

1. A method for producing a protein antigen which is reactive with an autoantibody associated with an autoimmune disease in a host, which comprises:

- 5 introducing genetic information from a gene library into plural recipient cells, wherein said gene library is obtained from a donor that expresses a protein antigen reactive with said autoantibody, thereby producing transformed cells;
- 10 selecting a transformed producer cell which contains a gene coding for said protein antigen, and which expresses said antigen by detecting a binding reaction between said autoantibody obtained from said host and a protein antigen expressed by said producer
- 15 cell thereby identifying a cloned DNA segment from said donor which can be utilized in the production of said protein.
2. The method of Claim 1, wherein said method further comprises the steps of cloning said selected
- 20 cell and isolating said protein antigen produced by said selected cells.
3. The method of Claim 1, which further comprises sequencing said gene or said peptide antigen and synthesizing said peptide by chemical means.
- 25 4. The method of Claim 1, wherein said donor gene library is a cDNA gene library.
5. The method of Claim 1, wherein said host is a human.

6. The method of Claim 1, wherein said autoimmune disease is systemic lupus erythematosus, rheumatoid arthritis, mixed cryoglobulinemia, thyroiditis, or glomerulonephritis.

5 7. The method of Claim 1, wherein said autoimmune disease is systemic lupus erythematosus.

8. The method of Claim 7, wherein said antigen is La, Ro, Scl, U₂bp, or L-42 antigen.

9. A recombinant DNA expression vector, wherein
10 said vector comprises an expressible DNA segment which codes for a protein antigen which is reactive with an autoantibody associated with an autoimmune disease.

10. The vector of Claim 9, wherein said segment codes for, at least 66 amino acids at the carboxy
15 terminal of a human La protein antigen.

11. A method for treating an autoimmune disease, which comprises:

injecting into a host afflicted with said disease a purified antigen reactive with an autoanti-
20 body associated with an autoimmune disease in said host in an amount sufficient to perturb the antigen-antibody ratio, thereby preventing the formation of new immune complexes or causing the disintegration of immune complexes which have already formed in the blood
25 of said host.

12. A peptide comprising a decapeptide region of sequence glu-asp-lys-thr-lys-ile-arg-arg-ser-pro that is reactive with an autoantibody having La specificity.

13. The peptide of Claim 12, wherein said peptide has an average hydrophilicity outside said decapeptide region of no more than +0.3.




FIG. 1A





FIG. 2

FIG. 1B






FIG. 4





FIG. 5

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No **PCT/US85/02493**

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ²		
According to International Patent Classification (IPC) or to both National Classification and IPC INT. Cl. 4 C12P 21/00, C12N 15/00, 1/00; A61K 39/00 A23J, C07K		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁴		
Classification System	Classification Symbols	
US	435/68, 172.3, 317; 424/85, 88 260/112R, 112.5R	
Documentation Searched other than Minimum Documentation to the extent that such Documents are Included in the Fields Searched ⁵		
COMPUTER DATA BASES: CHEM. ABSTRACTS DIALOG		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴		
Category ⁶	Citation of Document, ¹⁵ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
Y	N, Mathews et al, Molecular and Cellular Biology Vol. 4 No. 6 pp 1134-1140, June 1984	12,13
Y	N, Young et al, Science Vol. 222, pp 778-782, November 18, 1983	1-13
Y	N, Stefano, Cell Vol. 36, pp 145-154, January 1984	1-13
Y	N, Godson et al, Nature Vol. 305, pp 29-33, September 1, 1983	3
Y	US, A, 4,479,934, Published October 30, 1984	11
Y	US, A, 4,362,155, Published December 7, 1982	11
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁶ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ³		Date of Mailing of this International Search Report ³
2/25/86		04 MAR 1986
International Searching Authority ¹		Signature of Authorized Officer ²⁰
ISA/US		 Alvin E. Tanenholz

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.